Published by Contract Pharma 2019-01-28.

EirGenix Opens Mfg. Plant in Taiwan

Also inks ADC deal with Oncomatryx Biopharma

EirGenix, a contract development and manufacturing organization (CDMO) and a biosimilars maker, has opened a new protein production facility at the Hsinchu Biomedical Park in Zubei, Taiwan, boosting its CDMO capabilities.In addition to the new facility, the company, together with its parent, Formosa Labs, signed an agreement with Spain’s Oncomatryx Biopharma for the development of new antibody drug conjugates (ADCs).Since its formation in December 2012, EirGenix has completed more than 10 CDMO projects for overseas customers. It also operates a subsidiary, Formosa Pharmaceuticals, which offers new drug development services. It is currently building an injectable manufacturing plant with the goal of being a one-stop-shop from API manufacturing to drug product filling.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>


By continuing to use the site, you agree to the use of cookies. Continue, scroll or accept. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.